We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EU Approval Gives Amgen’s Repatha Edge Over Rival Praluent
EU Approval Gives Amgen’s Repatha Edge Over Rival Praluent
Regulators in the EU have cleared the way for Amgen to market its cholesterol-lowering drug Repatha, marking the world’s first approval of a PCSK9 inhibitor.